Tamar B Nobel1, Michael Curry2, Renee Gennarelli2, David R Jones3, Daniela Molena4. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Environmental Medicine and Public Health, Mount Sinai Hospital, New York, NY. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: molenad@mskcc.org.
Abstract
BACKGROUND: Esophageal cancer is considered a disease of the elderly. Although the incidence of esophageal adenocarcinoma in young patients is increasing, current guidelines for endoscopic evaluation of gastroesophageal reflux disease and Barrett's esophagus include age as a cutoff. There is a paucity of data on the presentation and treatment of esophageal cancer in young patients. Most studies are limited by small sample sizes, and conflicting findings are reported regarding delayed diagnosis and survival compared with older patients. METHODS: A retrospective cohort study was performed using the National Cancer Database between 2004 and 2015. Patients with esophageal adenocarcinoma were divided into quartiles by age (18-57, 58-65, 66-74, 75+ years) for comparison. Clinicopathologic and treatment factors were compared between groups. RESULTS: A total of 101,596 patients were identified with esophageal cancer. The youngest patient group (18-57 years) had the highest rate of metastatic disease (34%). No difference in tumor differentiation was observed between age groups. Younger patient groups were more likely to undergo treatment despite advanced stage at diagnosis. Overall 5-year survival was better for younger patients with local disease, but the difference was less pronounced in locoregional and metastatic cases. CONCLUSIONS: In this study, young patients were more likely to have metastatic disease at diagnosis. Advanced stage in young patients may reflect the need for more aggressive clinical evaluation in high-risk young patients.
BACKGROUND:Esophageal cancer is considered a disease of the elderly. Although the incidence of esophageal adenocarcinoma in young patients is increasing, current guidelines for endoscopic evaluation of gastroesophageal reflux disease and Barrett's esophagus include age as a cutoff. There is a paucity of data on the presentation and treatment of esophageal cancer in young patients. Most studies are limited by small sample sizes, and conflicting findings are reported regarding delayed diagnosis and survival compared with older patients. METHODS: A retrospective cohort study was performed using the National Cancer Database between 2004 and 2015. Patients with esophageal adenocarcinoma were divided into quartiles by age (18-57, 58-65, 66-74, 75+ years) for comparison. Clinicopathologic and treatment factors were compared between groups. RESULTS: A total of 101,596 patients were identified with esophageal cancer. The youngest patient group (18-57 years) had the highest rate of metastatic disease (34%). No difference in tumor differentiation was observed between age groups. Younger patient groups were more likely to undergo treatment despite advanced stage at diagnosis. Overall 5-year survival was better for younger patients with local disease, but the difference was less pronounced in locoregional and metastatic cases. CONCLUSIONS: In this study, young patients were more likely to have metastatic disease at diagnosis. Advanced stage in young patients may reflect the need for more aggressive clinical evaluation in high-risk young patients.
Authors: Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen Journal: Gastroenterology Date: 2011-03 Impact factor: 22.682
Authors: V Raman Muthusamy; Jenifer R Lightdale; Ruben D Acosta; Vinay Chandrasekhara; Krishnavel V Chathadi; Mohamad A Eloubeidi; Robert D Fanelli; Lisa Fonkalsrud; Ashley L Faulx; Mouen A Khashab; John R Saltzman; Aasma Shaukat; Amy Wang; Brooks Cash; John M DeWitt Journal: Gastrointest Endosc Date: 2015-04-08 Impact factor: 9.427
Authors: Erica Cohen; Roger Bolus; Dinesh Khanna; Ron D Hays; Lin Chang; Gil Y Melmed; Puja Khanna; Brennan Spiegel Journal: Dig Dis Sci Date: 2014-05-09 Impact factor: 3.199
Authors: Hans F Fuchs; Cristina R Harnsberger; Ryan C Broderick; David C Chang; Bryan J Sandler; Garth R Jacobsen; Michael Bouvet; Santiago Horgan Journal: Surg Endosc Date: 2016-09-22 Impact factor: 4.584